Akamai (AKAM) PT Raised to $65 at Stifel

Pre-Open Stock Movers 10/26: (OGXI) (AKAM) (IRBT) Higher; (EW) (NUVA) (P) (CMG) (AAPL) Lower (more...)

Today's Pre-Open Stock Movers

OncoGenex Pharmaceuticals, Inc. (Nasdq: OGXI) 32.3% HIGHER; announced positive survival results from the final analysis of the Phase 2 Borealis-2 trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy. Patients who received apatorsen treatment experienced a 20% reduction in risk of death, compared to patients receiving docetaxel alone (HR=.80; 95% CI: 0.65-0.98; p=0.078). The primary analysis was a superiority test of overall survival, performed at a one-sided 0.10 significance level using a stratified log-rank test. The trial was conducted by... More

RBC Capital Raises Price Target on Akamai Technologies (AKAM) to $67 Following Solid 3Q

RBC Capital reported a Sector Perform rating on Akamai Technologies (NASDAQ: AKAM), and raised the price target to $67.00 (from $59.00), following the company's 3Q earnings report. AKAM reported revenues of $584MM, above the Street's estimate $572MM. The beat was driven by stronger than expected results in... More

FBR Capital Upgrades Akamai Technologies (AKAM) to Market Perform

FBR Capital upgraded Akamai Technologies (NASDAQ: AKAM) from Underperform to Market Perform with a price target of $55.00.

Analyst David Dixon commented, "A surprising surge in the Performance and Securities Solutions segment more than offset an expected moderating decline in the Media Delivery Solutions business after tough comparables. Revenue contribution from the six... More

Akamai Technologies (AKAM): Revenue Growth Acceleration Should Lead To Multiple Expansion - Wells Fargo

Wells Fargo analyst, Gray Powell, reiterated his Outperform rating on shares of Akamai Technologies (NASDAQ: AKAM) and raised his valuation range to $71.00 to $74.00 from $59.00 to $62.00 after a beat and raise quarter.

The outperformance was driven by strength in the company's Performance and Security... More

Akamai Technologies (AKAM) Tops Q3 EPS by 7c

Akamai Technologies (NASDAQ: AKAM) reported Q3 EPS of $0.68, $0.07 better than the analyst estimate of $0.61. Revenue for the quarter came in at $584.1 million versus the consensus estimate of $571.87 million.

For earnings history and earnings-related data on Akamai Technologies (AKAM) click here.